Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy
Top Cited Papers
Open Access
- 3 July 2002
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 288 (1) , 49-57
- https://doi.org/10.1001/jama.288.1.49
Abstract
The Heart and Estrogen/progestin Replacement Study (HERS) was a randomized, blinded, placebo-controlled trial of the effect of 0.625 mg of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate daily on coronary heart disease (CHD) event risk among 2763 postmenopausal women with documented CHD.1 Overall, during 4.1 years of follow-up, there were no significant differences between the hormone and placebo groups in the primary outcome of CHD events (nonfatal myocardial infarction [MI] plus CHD-related death) or in any secondary cardiovascular outcomes.2-5 However, post-hoc analyses showed a statistically significant time trend, with more CHD events in the hormone group than in the placebo group during the first year of treatment, and fewer in years 3 to 5.2 HERS investigators speculated that early increased risk might be due to a prothrombotic, proarrhythmic, or proischemic effect of treatment that is gradually outweighed by a beneficial effect on the progression of underlying atherosclerosis mediated by the observed favorable changes in low- and high-density lipoprotein cholesterol.2Keywords
This publication has 13 references indexed in Scilit:
- Hormone treatment—misconceptions and agreementsPublished by Oxford University Press (OUP) ,2002
- Early risk of cardiovascular events after commencing hormone replacement therapyCurrent Opinion in Lipidology, 2001
- Risk of Recurrent Coronary Events in Relation to Use and Recent Initiation of Postmenopausal Hormone TherapyArchives of internal medicine (1960), 2001
- Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-upJournal of the American College of Cardiology, 2001
- Postmenopausal Hormone Therapy and Risk of StrokeCirculation, 2001
- Early Risks of Hormone Therapy in Patients With Coronary Heart DiseasePublished by American Medical Association (AMA) ,2000
- Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement StudyAnnals of Internal Medicine, 2000
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Intrinsic Fibrinolytic Capacity and Systemic Inflammation: Novel Risk Factors for Arterial Thrombotic DiseasePathophysiology of Haemostasis and Thrombosis, 1997
- Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacinJournal of the American College of Cardiology, 1986